Related Experiment Video
Updated: Dec 12, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.3K
Living safely with epilepsy: a key learning review.
Andrés Bertinat1, Mike Kerr2, Joyce A Cramer3
1Instituto de Neurología "Américo Ricaldoni", Facultad de Medicina, Universidad de la República, Uruguay.
Summary
This review provides guidance on counselling epilepsy patients to reduce seizure risks and injuries. It emphasizes personalized risk assessment and management to enhance patient independence and safety.
Area of Science:
- Neurology
- Public Health
Background:
- Epilepsy management includes risk reduction to maximize patient independence.
- Risk assessment and reduction are integral to the International League Against Epilepsy Curriculum for epileptology.
Purpose of the Study:
- To review key elements of epilepsy risk.
- To provide practical guidance for counselling and risk reduction strategies for epilepsy patients.
Main Methods:
- A review of key publications was conducted.
- Focus areas included seizure-related injury risks, lifestyle safety, Sudden Unexpected Death in Epilepsy (SUDEP) risk and avoidance, and individual risk assessment.
Main Results:
- Epilepsy risks are common and multifactorial, influenced by seizure type, lifestyle, and activities.
- Transcultural differences in risk factors (e.g., SUDEP, driving regulations) require consideration.
- Individual risk assessment is improving with better understanding of risk factors and methodologies.
Conclusions:
- Clinicians must be aware of diverse risk factors in epilepsy.
- Counselling should empower patients to identify and manage their individual risks.
- Effective risk management enhances safety and independence for people with epilepsy.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.0K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
01:13Seizures: Classification
1.1K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
498
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
498
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
689
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
689
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.4K
01:30Electroconvulsive Therapy
508
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
508